Johnson & Johnson (JNJ)
NYSE: JNJ · IEX Real-Time Price · USD
160.64
+1.00 (0.63%)
At close: Jul 26, 2024, 4:00 PM
160.48
-0.16 (-0.10%)
After-hours: Jul 26, 2024, 7:36 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $22.45B in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $86.58B, down -11.02% year-over-year. In the year 2023, Johnson & Johnson had annual revenue of $85.16B with 6.46% growth.
Revenue (ttm)
$86.58B
Revenue Growth
-11.02%
P/S Ratio
4.93
Revenue / Employee
$596,763
Employees
131,900
Market Cap
386.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
| Dec 28, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 379.49B |
| Merck & Co. | 61.40B |
| AbbVie | 54.40B |
| Novartis AG | 48.86B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
| Eli Lilly | 35.93B |
JNJ News
- 10 hours ago - Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan - Business Wire
- 10 hours ago - FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan - Business Wire
- 12 hours ago - Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - GlobeNewsWire
- 3 days ago - Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire
- 4 days ago - Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan - Business Wire
- 4 days ago - Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat? - Forbes
- 4 days ago - Women Urge Support for $8 Billion J&J Talcum Powder Settlement as July 26th Deadline Approaches - Business Wire
- 4 days ago - Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression - PRNewsWire